| Amgen's Hopes for Prolia Go Beyond Osteoporosis Therapy The Burrill Report submits: By Michael FitzhughAmgen (AMGN) won an earlier-than-expected FDA approval for denosumab, its treatment for postmenopausal women with osteoporosis at high risk for bone fractures, just days after European regulators approved the drug. Sales of the injectable medicine, to be marketed as Prolia, could generate as much as $942 million in 2011, according to consensus analyst estimates from Bloomberg. Sources polled by EvaluatePharma predicted sales of $5.32 billion by 2016.Complete Story » seekingalpha.com |
Ranbaxy Transfers New Drug Research Operations Ranbaxy transferred its new drug discovery research capabilities to Japanese parent Daiichi Sankyo. online.wsj.com |
U.K. Watchdog Rejects Gleevec Britain's cost watchdog said it won't recommend Novartis's key oncology drug as a follow-up treatment for certain stomach-cancer patients due to cost/benefit considerations. online.wsj.com |
FDA Panel Splits On Meridia's Fate An expert panel advising the FDA on the weight-loss drug Meridia split on whether it should be removed from pharmacy shelves due to concerns about risks of heart problems and strokes. online.wsj.com |
New Trial: www.DUETStrial.com - Video Device for Women with Bladder Control Issues May Be an Effective Alternative to Medication and Surgery feedproxy.google.com |